Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | ADA | P00813 | 1/20 | 0.52 |
| ▸ | PGK1 | P00558 | 1/20 | 0.51 |
| ▸ | PGK2 | P07205 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24081925 | 0.86 | ADORA3 (0.66) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL30091060 | 0.86 | ADORA3 (0.66) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL21136929 | 0.86 | ADORA3 (0.66) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL723793 | 0.86 | ADORA3 (0.66) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL3924548 | 0.86 | ADORA3 (0.66) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL5937302 | 0.85 | ADORA2A (0.59) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL723669 | 0.84 | ADORA3 (0.76) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL10208341 | 0.84 | ADORA3 (0.76) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL15618022 | 0.83 | ADORA1 (0.74) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL21136562 | 0.83 | ADORA1 (0.74) | ADORA2AADORA3ADORA1ADORA2BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278990-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278990-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150038451-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038451-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8871737-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871737-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2012040127-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | ADORA2A 252/4885ADORA3 216/4885ADORA1 240/4885 |
| US-20150038451-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | ADORA2A 252/4885ADORA3 216/4885ADORA1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.